metformin has been researched along with Abnormalities, Jaw in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Accordingly, O304 reduced fasting plasma glucose levels and homeostasis model assessment of insulin resistance (HOMA-IR) in a proof-of-concept phase IIa clinical trial in type 2 diabetes (T2D) patients on Metformin." | 3.88 | PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. ( Backlund, F; Berggren, E; Bergqvist, I; Dahl, U; Edlund, H; Edlund, T; Ericsson, M; Eriksson, B; Kjellkvist, E; Lidh, E; Lindahl, E; Linde, K; Lundberg, I; Steneberg, P; Straseviciene, J; Westman, J, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Steneberg, P | 1 |
| Lindahl, E | 1 |
| Dahl, U | 1 |
| Lidh, E | 1 |
| Straseviciene, J | 1 |
| Backlund, F | 1 |
| Kjellkvist, E | 1 |
| Berggren, E | 1 |
| Lundberg, I | 1 |
| Bergqvist, I | 1 |
| Ericsson, M | 1 |
| Eriksson, B | 1 |
| Linde, K | 1 |
| Westman, J | 1 |
| Edlund, T | 1 |
| Edlund, H | 1 |
1 other study available for metformin and Abnormalities, Jaw
| Article | Year |
|---|---|
PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Blood Pressure; Cardiomegaly; Cardiovascular | 2018 |